Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Hematologic Malignancy Reports
Erschienen in: Current Hematologic Malignancy Reports 2/2024

10.02.2024

Frontline Therapy of CLL—Changing Treatment Paradigms

verfasst von: Catherine C. Coombs

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The therapeutic landscape for chronic lymphocytic leukemia (CLL) has undergone a complete makeover following the introduction of highly effective targeted therapies, beginning with ibrutinib which first attained regulatory approval for CLL in 2014.

Recent Findings

In recent years, we have seen further refinement of therapeutic options with the development of newer-generation Bruton’s tyrosine kinase inhibitors (BTKi) including acalabrutinib and zanubrutinib that improve upon the safety of ibrutinib. Additionally, venetoclax-based approaches, combined with anti-CD20 antibodies, have allowed for time-limited targeted therapeutic strategies which are particularly attractive for certain subsets of patients though have demonstrated efficacy across all subgroups. Lastly, there is an ongoing movement toward the development of time-limited strategies inclusive of both a BTKi and venetoclax that may further widen potential options.

Summary

CLL patients requiring frontline therapy have a unique burden of choice between highly effective therapies that differ substantially with respect to side effect profiles and schedules. This review will focus on the frontline management of CLL in the setting of these rapidly changing options.
Literatur
1.
Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–74.PubMedCrossRef
2.
Eichhorst B, Fink A-M, Bahlo J, Busch R, Kovacs G, Maurer C, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928–42.PubMedCrossRef
3.
International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779–90.CrossRef
4.
Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–6.PubMedCrossRef
5.
Kittai AS, Miller C, Goldstein D, Huang Y, Abruzzo LV, Beckwith K, et al. The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib. Blood. 2021;138(23):2372–82.PubMedCrossRef
6.
Fürstenau M, Thus YJ, Robrecht S, Mellink CHM, van der Kevie-Kersemaekers A-MF, Dubois J, et al. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations. Blood. 2023;142(5):446–59.
7.
Rigolin GM, Cavallari M, Quaglia FM, Formigaro L, Lista E, Urso A, et al. In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI. Blood. 2017;129(26):3495–8.PubMedCrossRef
8.
Baliakas P, Espinet B, Mellink C, Jarosova M, Athanasiadou A, Ghia P, et al. Cytogenetics in chronic lymphocytic leukemia: ERIC perspectives and recommendations. HemaSphere. 2022;6(4): e707.PubMedPubMedCentralCrossRef
9.
Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28(29):4473–9.PubMedCrossRef
10.
Zenz T, Kröber A, Scherer K, Häbe S, Bühler A, Benner A, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood. 2008;112(8):3322–9.PubMedCrossRef
11.
Parikh SA, Rabe KG, Kay NE, Call TG, Ding W, Leis JF, et al. The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. Blood. 2021;138(2):149–59.PubMedPubMedCentralCrossRef
12.
Langerbeins P, Zhang C, Robrecht S, Cramer P, Fürstenau M, Al-Sawaf O, et al. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. Blood. 2022;139(2):177–87.PubMedCrossRef
13.
Langerbeins P, Robrecht S, Nieper P, Cramer P, Fürstenau M, Al-Sawaf O, et al. Ibrutinib versus placebo in patients with asymptomatic, treatment-naive early stage chronic lympho- cytic leukemia (CLL): final results of the phase 3, double- blind, placebo controlled CLL12 trial. Hematol Oncol. 2023;41(S2):56–8.CrossRef
14.
Stephens DM, Moseley A, Hill BT, Pagel JM, Shadman M, Fisch MJ, et al. Randomized, phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): EVOLVE CLL/SLL study (SWOG S1925, NCT#04269902). JCO. 2021;39(15_suppl):TPS7567.CrossRef
15.
Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208–15.PubMedCrossRef
16.
Thompson PA, Tam CS, O’Brien SM, Wierda WG, Stingo F, Plunkett W, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127(3):303–9.PubMedPubMedCentralCrossRef
17.
Benjamini O, Jain P, Trinh L, Qiao W, Strom SS, Lerner S, et al. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma. 2015;56(6):1643–50.PubMedCrossRef
18.
Carney DA, Westerman DA, Tam CS, Milner A, Prince HM, Kenealy M, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia. 2010;24(12):2056–62.PubMedCrossRef
19.
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–37.PubMedPubMedCentralCrossRef
20.
Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6(11):3440–50.PubMedPubMedCentralCrossRef
21.
• Shanafelt TD, Wang XV, Kay NE, Hanson CA, O’Brien S, Barrientos J, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432–43 This trial demonstrated an overall survival advantage for patients receiving ibrutinib with rituximab as compared to the FCR regimen.
22.
•• Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O’Brien S, Barrientos J, et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140(2):112–20 Longer-term follow-up of the E1912 trial of ibrutinib with rituximab versus FCR confirmed the overall survival advantage and also demonstrated a progression-free survival advantage for both mutated and unmutated IGHV patients.
23.
Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, et al. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(5):535–52.PubMedCrossRef
24.
Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–28.PubMedPubMedCentralCrossRef
25.
Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019;133(10):1011–9.PubMedPubMedCentralCrossRef
26.
•• Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278–91 This trial demonstrated superior progression-free survival for frontline use of acalabrutinib (alone or with obinutuzumab) as compared to chlorambucil with obinutuzumab.
27.
Sharman JP, Egyed M, Jurczak W, Skarbnik AP, Kamdar MK, Munir T, et al. Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: five-year follow-up of ELEVATE-TN. JCO. 2022;40(16_suppl):7539–7539.CrossRef
28.
Shadman M, Munir T, Roback T, Brown JR, Kahl BS, Ghia P, et al. Zanubrutinib (ZANU) versus bendamustine + rituximab (BR) in patients (PTS) with treatment naïve (TN) CLL/SLL: extended follow up of the SEQUOIA study. Hematol Oncol. 2023;41(S2):235–8.CrossRef
29.
Gordon MJ, Jones JE, George B, Peterson C, Burger JA, Jain N, et al. Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: focus on hypertension and cardiovascular toxicity. Cancer. 2023;129(14):2192–200.PubMedCrossRef
30.
Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39(31):3441–52.PubMedPubMedCentralCrossRef
31.
Seymour JF, Byrd JC, Ghia P, Kater AP, Chanan-Khan AA, 645 Furman RR, et al. Detailed safety profile of acalabrutinib vs 646 ibrutinib in previously treated chronic lymphocytic leukemia in 647 ELEVATE-RR. Blood 2023;142(8):687–699.
32.
Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388(4):319–32.PubMedCrossRef
33.
•• Fischer K, Al-Sawaf O, Bahlo J, Fink A-M, Tandon M, Dixon M, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–36 This trial demonstrated superior progression-free survival for frontline use of time-limited venetoclax with obinutuzumab as compared to chlorambucil with obinutuzumab.
34.
Al-Sawaf O, Zhang C, Jin HY, Robrecht S, Choi Y, Balasubramanian S, et al. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nat Commun. 2023;14(1):2147.ADSPubMedPubMedCentralCrossRef
35.
•• Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, et al. First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med. 2023;388(19):1739–54 This trial demonstrated superior progression-free survival for frontline use of time-limited venetoclax with obinutuzumab as compared to chemoimmunotherapy regimens (FCR and BR).
36.
Huang Q, Deering KL, Harshaw Q, Leslie LA. Real-world clinical outcomes of first-line ibrutinib or chemoimmunotherapy in patients with chronic lymphocytic leukemia by risk status. Adv Ther. 2022;39(7):3292–307.PubMedPubMedCentralCrossRef
37.
Brown JR, Hallek MJ, Pagel JM. Chemoimmunotherapy versus targeted treatment in chronic lymphocytic leukemia: when, how long, how much, and in which combination? Am Soc Clin Oncol Educ Book. 2016;35:e387–98.PubMedCrossRef
38.
•• Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23(8):1031–43 This trial demonstrated superior progression-free survival for zanubrutinib as compared to BR regimen.
39.
Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang YM, Fink 52. A-M, et al. Venetoclax obinuzutuab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study. HemaSphere | 2023;7(S3).
40.
Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, et al. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. Am J Hematol. 2018;93(11):1394–401.PubMedPubMedCentralCrossRef
41.
Rigolin GM, Olimpieri PP, Summa V, Celant S, Scarfò L, Tognolo L, et al. Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency. Blood Cancer J. 2023;13(1):99.PubMedPubMedCentralCrossRef
42.
Allan JN, Shanafelt T, Wiestner A, Moreno C, O’Brien SM, Li J, et al. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials. Br J Haematol. 2022;196(4):947–53.PubMedCrossRef
43.
• Tam CS, Robak T, Ghia P, Kahl BS, Walker P, Janowski W, et al. Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion. Haematologica. 2020;106(9):2354–63 Patients with deletion 17p who receive frontline therapy with zanubrutinib have excellent responses in this non-randomized study.
44.
Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018;36(19):1973–80.PubMedCrossRef
45.
Visentin A, Mauro FR, Scarfò L, Gentile M, Farina L, Reda G, et al. Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: a chronic lymphocytic leukemia campus study. Am J Hematol. 2023;98(9):E237–40.PubMedCrossRef
46.
Kater AP, Owen C, Moreno C, Follows G, Munir T, Levin M-D, et al. Fixed-duration ibrutinib-venetoclax in patients with 59. chronic lymphocytic leukemia and comorbidities. NEJM Evid 2022;1(7).
47.
• Allan JN, Flinn IW, Siddiqi T, Ghia P, Tam CS, Kipps TJ, et al. Outcomes in patients with high-risk features after fixed-duration ibrutinib plus venetoclax: phase II CAPTIVATE study in first-line chronic lymphocytic leukemia. Clin Cancer Res. 2023;29(14):2593–601. Several studies have pointed to high efficacy when using a BTKi and venetoclax doublet.
48.
• Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, et al. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 2022;139(22):3278–89 Several studies have pointed to high efficacy when using a BTKi and venetoclax doublet.
49.
• Munir T, Moreno C, Owen C, Follows G, Benjamini O, Janssens A, et al. Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in the GLOW study. J Clin Oncol. 2023;41(21):3689–99 Several studies have pointed to high efficacy when using a BTKi and venetoclax doublet.
50.
• Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial. JAMA Oncol. 2021;7(8):1213–9 Several studies have pointed to high efficacy when using a BTKi and venetoclax doublet.
51.
Tedeschi A, Ferrant E, Flinn IW, Tam CS, Ghia P, Robak T, et al. Zanubrutinib in combination with venetoclax for patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): early results from Arm D of the SEQUOIA (BGB-3111-304) trial. Blood. 2021;138(Supplement 1):67–67.CrossRef
52.
Cheah CY, Tam CS, Lasica M, Verner E, Browett PJ, Anderson MA, et al. A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor Bgb-11417 as monotherapy or in combination with zanubrutinib (ZANU) in patients (Pts) with CLL/SLL: preliminary data. Blood. 2022;140(Supplement 1):2321–3.CrossRef
53.
Rogers KA, Huang Y, Ruppert AS, Abruzzo LV, Andersen BL, Awan FT, et al. Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-naïve and relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38(31):3626–37.PubMedPubMedCentralCrossRef
54.
Rogers KA, Huang Y, Ruppert AS, Awan FT, Heerema NA, Hoffman C, et al. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. Blood. 2018;132(15):1568–72.PubMedPubMedCentralCrossRef
55.
Huber H, Edenhofer S, von Tresckow J, Robrecht S, Zhang C, Tausch E, et al. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia. Blood. 2022;139(9):1318–29.PubMedCrossRef
56.
Davids MS, Lampson BL, Tyekucheva S, Wang Z, Lowney JC, Pazienza S, et al. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. Lancet Oncol. 2021;22(10):1391–402.PubMedCrossRef
57.
Soumerai JD, Mato AR, Dogan A, Seshan VE, Joffe E, Flaherty K, et al. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2021;8(12):e879–90.PubMedPubMedCentralCrossRef
58.
Woyach JA, Yin J, Brown JR, Dinner S, Lozanski G, Little RF, et al. Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance). JCO. 2023;41(16_suppl):7500.CrossRef
59.
Ryan CE, Lampson BL, Tyekucheva S, Hackett LR, Ren Y, Shupe SJ, et al. Updated results from a multicenter, phase 2 study of acalabrutinib, venetoclax, obinutuzumab (AVO) in a population of previously untreated patients with CLL enriched for high-risk disease. Blood. 2022;140(Supplement 1):837–8.CrossRef
60.
Ryan CE, Davids MS, Hermann R, Shahkarami M, Biondo J, Abhyankar S, et al. MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Future Oncol. 2022;18(33):3689–99.PubMedCrossRef
61.
Kater A, Harrup R, Kipps T, Eichhorst B, Owen C. Final 7-year follow up and retreatment substudy analysis of MURANO venetoclax-rituximab (VENR)-treated patients with relapsed/ refractory chronic lymphocytic leukemia. Hemasphere. 2023;7(Suppl):e492813f.
62.
Thompson MC, Harrup RA, Coombs CC, Roeker LE, Pu JJ, Choi MY, et al. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. Blood Adv. 2022;6(15):4553–7.PubMedPubMedCentralCrossRef
63.
Davids MS, Fischer K, Robrecht S, Zhang C, Ahn IE, PorroLurà M, et al. ReVenG: A phase 2 study of venetoclax plus obinutuzumab retreatment in patients with relapsed chronic lymphocytic leukemia. Blood. 2021;138(Supplement 1):2634–2634.CrossRef
64.
Fisher A, Goradia H, Martinez-Calle N, Patten P, Munir T. The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials. Front Oncol. 2023;22(13):1130617.CrossRef
65.
Rios-Olais FA, Hilal T. Measurable residual disease in chronic lymphocytic leukemia: current understanding and evolving role in clinical practice. Curr Treat Options Oncol. 2023;24(8):907–28.PubMedCrossRef
Metadaten
Titel
Frontline Therapy of CLL—Changing Treatment Paradigms
verfasst von
Catherine C. Coombs
Publikationsdatum
10.02.2024
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 2/2024
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-024-00726-x

Weitere Artikel der Ausgabe 2/2024

Current Hematologic Malignancy Reports 2/2024 Zur Ausgabe

ReviewPaper

Telomere Biology Disorder: A Focus on Gastrointestinal and Hepatic Manifestations

ReviewPaper

How Do We Manage Chronic Lymphocytic Leukemia in India

ReviewPaper

Treatment of Richter’s Transformation with Novel Therapies

ReviewPaper

Transplantation and Cellular Therapy for Older Adults—The MSK Approach

Neu im Fachgebiet Onkologie

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise